NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +46.01%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.42 per share when it actually produced a loss of $0.33, delivering a surprise of +21.43%.Over the last four quarters, the company ...

Leonard said the company’s glioblastoma (GBM) business remains core. In 2025, NovoCure saw active patient growth across major markets, driven primarily outside the U.S. He cited year-over-year active patient growth of 10% in Germany, 19% in France and 29% in Japan, along with 4% growth in the U.S., which he said had been flat in recent years. For 2026, management expects growth rates to stabilize in the “low to mid-single digit” range as markets mature, with modest first-year contributions expected from lau ...

NovoCure (NasdaqGS:NVCR) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristoph Brackmann - CFOEmily Bodnar - VP, Equity ResearchFrank Leonard - CEOIngrid Goldberg - Head of Investor RelationsWilliam F. Doyle - Executive ChairmanConference Call ParticipantsAlbert Augustinus - AnalystJason Bednar - Managing Director and Senior Research AnalystNone - AnalystNone - AnalystOperatorThank you for standing by. Welcome to the Novocure Fourth Quarter 2025 Earnings Call. At this time, all p ...

NovoCure (NasdaqGS:NVCR) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker6Thank you for standing by. Welcome to the Novocure Fourth Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press sta ...

forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, man ufa cturing developmen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________ FORM 10-K ______________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Address of Princi ...

Core Viewpoint - Novocure (NVCR) has received FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, ahead of the expected timeline of Q2 2026 [1][2] Company Developments - The FDA approval is based on the successful phase III study, PANOVA-3, which showed that Optune Pax combined with gem/nab-pac significantly improved overall survival compared to gem/nab-pac alone [2][9] - Novocure has other commercialized therapies using Tumor Treating Fields (TTFields), including Optune Gio for glioblastoma multiforme and Optune Lua for metastatic non-small cell lung cancer [3] - The company is also developing therapies for treating metastatic pancreatic cancer and newly diagnosed glioblastoma multiforme [3] Clinical Data - The PANOVA-3 study demonstrated a median overall survival (mOS) of 16.2 months for patients treated with Optune Pax and gem/nab-pac, compared to 14.2 months for those receiving gem/nab-pac alone [8][10] - The one-year survival rate was 68.1% for the Optune Pax group versus 60.2% for the gem/nab-pac group [10] - Additionally, the median time to pain progression improved to 15.2 months with Optune Pax compared to 9.1 months for gem/nab-pac alone [10] Market Potential - The pancreatic cancer market is projected to grow from $3.01 billion to $9.57 billion between 2025 and 2034, at a CAGR of 13.7%, driven by increasing cases and advancements in treatment options [12] - The approval of Optune Pax is expected to enhance Novocure's market prospects, given the limited treatment options currently available for pancreatic cancer [12] Financial Performance - Novocure reported preliminary net revenues of $174.4 million for Q4 and full-year 2025, reflecting an 8% year-over-year increase, with total revenues for the year reaching $655 million [13]

对于中国临床医生、胰腺癌患者以及医疗器械产业而言，一项刚获监管批准的新技术值得关注： 一种无需开刀、无需放疗、通过可穿戴设备持续释放电场干扰肿瘤 分裂的治疗方式，已在美国获批用于局部晚期胰腺癌。注意：该疗法尚未在中国上市， 但其治疗机制、设备形态及临床结果，可供国内专业人士参考，思宇 MedTech专门整理分析。 胰腺癌长期被认为是最具挑战性的实体肿瘤之一：起病隐匿、确诊多为晚期、药物渗透困难、总体预后极差。几十年来，一线治疗虽持续优化，但疗效改善有限。 因此，任何能够改善生存与生活质量的新路径，都会引发全球关注。 2026年2月，美国FDA 批准 Novocure公司 的 Optune Pax 系统，用于局部晚期胰腺癌，并与吉西他滨（gemcitabine）联合白蛋白结合型紫杉醇（nab-paclitaxel）联合 使用。FDA指出，该系统通过肿瘤电场治疗技术（TTFields）提供一种不同于传统药物或放疗的治疗路径。 # 一种"生物物理路径"的抗肿瘤机制 Optune Pax采用 Tumor Treating Fields（TTFields）技术，通过贴附于腹部皮肤的电极阵列向肿瘤区域输送低强度交变电场。 ...

Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central, which includes a model portfolio and extensive research articles [1][2]. Group 1: Company Overview - Biotech Analysis Central provides a subscription service that includes over 600 articles focused on Biotech investing, aimed at helping investors make informed decisions [2]. - The service offers a model portfolio consisting of more than 10 small and mid-cap stocks, each accompanied by detailed analysis [2]. Group 2: Subscription Details - The monthly subscription fee for Biotech Analysis Central is $49, with a discounted annual plan available at $399, representing a 33.50% savings for yearly subscribers [1].

Core Viewpoint - The article discusses the stock movements of several companies including Cisco, AppLovin, Micron, Fastly, Equinix, Rollins, and Novocure, highlighting the impact of recent economic data on investor sentiment [1]. Group 1: Stock Movements - Cisco's stock performance is noted among the movers, indicating potential investor interest or market reaction [1]. - AppLovin's stock is also mentioned, suggesting fluctuations that may be tied to broader market trends or company-specific news [1]. - Micron's stock movement is highlighted, reflecting changes in the semiconductor industry and investor confidence [1]. Group 2: Economic Context - The article references a recent batch of economic data, including a delayed U.S. monthly jobs report, which is influencing stock futures and overall market sentiment [1]. - The rising stock futures on Thursday indicate a positive outlook among investors as they digest the latest economic indicators [1].